## **Core Concept**
Antenatal screening for Down syndrome involves various tools to assess the risk of the condition in a fetus. These tools can include maternal age, ultrasound markers (such as nuchal translucency), and biochemical markers (like serum free beta-hCG and PAPP-A). The goal is to identify pregnancies at higher risk for Down syndrome.

## **Why the Correct Answer is Right**
The correct answer, , indicates a marker or condition that does NOT suggest an increased risk of Down syndrome. Typically, increased nuchal translucency (NT), high levels of free beta-hCG, low levels of PAPP-A, and advanced maternal age are associated with an increased risk of Down syndrome. A marker that does not indicate an increased risk would be one that is either protective or not associated with Down syndrome.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Increased nuchal translucency is associated with an increased risk of Down syndrome. Therefore, it is not the correct answer.
- **Option B:** High levels of free beta-hCG are linked to an increased risk of Down syndrome, making this option incorrect.
- **Option C:** Low PAPP-A levels are associated with an increased risk of Down syndrome, which makes this option incorrect as well.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that a normal or low nuchal translucency does not entirely rule out Down syndrome but significantly reduces the risk. Screening tools are used to stratify risk, and a high-risk result does not confirm Down syndrome but warrants further diagnostic testing like amniocentesis or chorionic villus sampling.

## **Correct Answer: .**